Inspire Investing LLC Has $410,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Inspire Investing LLC trimmed its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 12.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,915 shares of the biopharmaceutical company’s stock after selling 691 shares during the quarter. Inspire Investing LLC’s holdings in Intra-Cellular Therapies were worth $410,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC boosted its holdings in shares of Intra-Cellular Therapies by 204.4% during the 4th quarter. SG Americas Securities LLC now owns 12,917 shares of the biopharmaceutical company’s stock valued at $1,079,000 after acquiring an additional 8,673 shares in the last quarter. Cetera Trust Company N.A grew its holdings in shares of Intra-Cellular Therapies by 17.3% during the fourth quarter. Cetera Trust Company N.A now owns 2,955 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 435 shares during the last quarter. Barlow Wealth Partners Inc. acquired a new position in shares of Intra-Cellular Therapies in the fourth quarter valued at approximately $184,000. Oak Ridge Investments LLC raised its holdings in Intra-Cellular Therapies by 74.1% in the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after buying an additional 8,440 shares during the last quarter. Finally, Merit Financial Group LLC acquired a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $206,000. Institutional investors own 92.33% of the company’s stock.

Insider Activity at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. 2.60% of the stock is owned by company insiders.

Intra-Cellular Therapies Trading Up 0.2 %

NASDAQ ITCI opened at $127.35 on Friday. The firm has a market capitalization of $13.50 billion, a P/E ratio of -146.38 and a beta of 0.70. The business has a fifty day simple moving average of $93.20 and a 200 day simple moving average of $82.78. Intra-Cellular Therapies, Inc. has a 12 month low of $62.78 and a 12 month high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $175.40 million during the quarter, compared to the consensus estimate of $172.30 million. During the same period in the prior year, the company earned ($0.25) earnings per share. The business’s revenue was up 39.0% on a year-over-year basis. As a group, sell-side analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ITCI. Morgan Stanley raised their price target on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Needham & Company LLC reaffirmed a “hold” rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday. Finally, Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $102.15.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.